

## **Media Release**

### **Innovation in blood glucose management – Solianis Monitoring AG has entered a co-operation with the University Hospital of Zurich**

*Ps. Zurich, March 23, 2006:* Solianis Monitoring AG, based in Zurich, has taken another step on the way to a truly non-invasive blood glucose monitor. It has signed an agreement for a clinical study together with the *Center of Medical Research of the University Hospital of Zurich*.

In this trial the non-invasive sensor concept currently under development will be tested for the first time on patients with diabetes. The study is designed to run for two years but first results will be available this summer, indicating the reliability of the technology developed by Solianis.

*The Ethics Commission of the Canton of Zurich* has approved the clinical trial, the authorization of the supervisory authority *Swissmedic* is under way.

The CEO of Solianis Monitoring AG, Mario Stark, is satisfied with the rapid progress of the project: “We are very pleased that we found such a renowned and competent partner like the *University Hospital of Zürich* to collaborate with for our clinical trial. Our very professional team is proud and highly motivated to press on with the development of our technology. Together with the experts of the *Center of Medical Research* we will take a significant step forward to help patients with diabetes with our non-invasive glucose monitor.”

Contact: Mario Stark, CEO  
Solianis Monitoring AG  
Leutschenbachstrasse 46  
CH-8050 Zurich  
Tel +41 79 542 88 74